BIO

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, its products advance the discovery process and improve healthcare. Bio-Rad's customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology and pharmaceutical companies, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 7,800 employees worldwide. Bio-Rad had revenues exceeding $2.5 billion in 2020.
CEO
Norman Schwartz
Employees
8000
Headquarters

1000 Alfred Nobel Dr
Hercules, California 94547-1811
Phone: 15107247000
www.bio-rad.com

News

3 Beaten-Down Biotech Stocks Bound for a Bounce Back
Sep 02, 2023 11:38am

Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market when the pandemic was over. Biotech stocks as a whole have dropped considerably from their pandemic-era highs. Although these stocks have been hit hard lately, some of these investments present long-term opportunities for a savvy investor. Biotechnology is still the wave of the future, with new discoveries helping to treat once-untreatable diseases. New biotech labs still need new equipment to make tomorrow’s new discoveries. As our population ages and diseases become more prevalent, the healthcare industry is set to outpace the economy. The biotech industry will be growing right alongside it. The best-undervalued biotech picks are those that have likely been oversold due to investor skittishness amid rising interest rates. While speculative drug plays aren’t a guarantee of success, many companies are much more well-positioned than people realize.


Source:InvestorPlace
Tower Research Capital LLC TRC Increases Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Aug 23, 2023 10:16am

Tower Research Capital LLC TRC raised its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 88.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 915 shares of the medical research company’s stock after purchasing an additional 430 shares during the quarter. […]


Source:The AM Reporter
Credit Suisse maintains Bio-Rad Labs at ''outperform'' with a price target of $550.00
Aug 04, 2023 09:29am

https://www.investing.com/news/pro/biorad-laboratories-inc-receives-investment-bank-analyst-rating-update-3144908


Source:Investing.com
Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Call Transcript
Aug 04, 2023 03:33am

Bio-Rad Laboratories, Inc. (NYSE:NYSE:BIO) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ETCompany ParticipantsEdward Chung - Head, Investor RelationsNorman Schwartz - Chief…


Source:Seeking Alpha
Bio-Rad Labs Non-GAAP EPS of $3.00 beats by $0.32, revenue of $681.11M misses by $14.72M
Aug 03, 2023 20:47pm

Bio-Rad Labs press release (BIO): Q2 Non-GAAP EPS of $3.00 beats by $0.32.Revenue of $681.11M (-1.4% Y/Y) misses by $14.72M.Updated 2023 Outlook: The company currently expects…


Source:Seeking Alpha
Bio-Rad Labs Q2 2023 Earnings Preview
Aug 02, 2023 21:35pm

Bio-Rad Labs (BIO) is scheduled to announce Q2 earnings results on Thursday, August 3rd, after market close.


Source:Seeking Alpha
Texas Permanent School Fund Corp Has $2.15 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)
Jul 30, 2023 09:30am

Texas Permanent School Fund Corp boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO – Free Report) by 46.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,489 shares of the medical research company’s stock after purchasing an additional 1,430 shares during the period. […]


Source:The AM Reporter